Azevan Pharmaceuticals
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
116 Research Dr, Bethlehem, Pennsylvania...Phone Number
(610) 419-1057Website
www.azevan.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Azevan Pharmaceuticals
Azevan is a clinical-stage drug development company focused on advancing first-in-class, orally bioavailable vasopressin 1a receptor (V1aR) antagonists for treating stress-related CNS disorders, traumatic brain injury, and neurodevelopmental diseases. The company's innovative approach targets the dysregulated arginine vasopressin signaling that contributes to various neuropsychiatric and neurodevelopmental conditions, offering a mechanism-based strategy for symptom control. Azevan's development strategy emphasizes addressing significant unmet medical needs, particularly in rare diseases and conditions like Huntington's disease, Fragile X syndrome, and mild traumatic brain injury. With ongoing clinical trials and collaborations, Azevan aims to provide effective treatments where current options are limited or absent.Explore more
Azevan Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Azevan Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Azevan Pharmaceuticals
Check if Azevan Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Azevan Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Azevan Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Azevan Pharmaceuticals has new funding data
Click to see if Azevan Pharmaceuticals had a recent Job posting/layoffs
Azevan Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Azevan Pharmaceuticals launches new products
Recommended Actions
Reach out to Masked Content who joined Azevan Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Azevan Pharmaceuticals
Compare insights from companies similar to Azevan Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Company Profile Activity
Activity Insights
Azevan Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Azevan Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Azevan Pharmaceuticals.
Azevan Pharmaceuticals financials insights
Gather financial insights about Azevan Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$2.2M
Azevan Pharmaceuticals Tech Stack
A closer look at the technologies used by Azevan Pharmaceuticals
Azevan Pharmaceuticals News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Azevan Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Azevan is a clinical-stage drug development company focused on advancing first-in-class, orally bioavailable vasopressin 1a receptor (V1aR) antagonists for treating stress-related CNS disorders, traumatic brain injury, and neurodevelopmental diseases. The company's innovative approach targets the dysregulated arginine vasopressin signaling that con... Read More
